Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation – in patients with locally advanced or metastatic non-small-cell lung cancer.
Find more on Medicine Matters oncology
More from WCLC 2019
You'll still be able to report anonymously.